Catalent - CTLT Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTLT shares.
View CTLT analyst ratings or view top-rated stocks.

9 analysts have issued 1-year target prices for Catalent's shares. Their CTLT share price forecasts range from $78.00 to $145.00. On average, they predict the company's stock price to reach $96.30 in the next twelve months. This suggests a possible upside of 49.8% from the stock's current price.
View analysts price targets for CTLT or view top-rated stocks among Wall Street analysts.

Catalent's stock was trading at $45.01 on January 1st, 2023. Since then, CTLT shares have increased by 42.8% and is now trading at $64.27.
View the best growth stocks for 2023 here.

Catalent saw a decline in short interest in the month of February. As of February 15th, there was short interest totaling 5,240,000 shares, a decline of 20.7% from the January 31st total of 6,610,000 shares. Based on an average trading volume of 2,930,000 shares, the days-to-cover ratio is currently 1.8 days.
View Catalent's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our CTLT earnings forecast.

Catalent, Inc. (NYSE:CTLT) announced its earnings results on Tuesday, February, 7th. The company reported $0.62 EPS for the quarter, missing the consensus estimate of $0.64 by $0.02. The company had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.12 billion. Catalent had a net margin of 8.62% and a trailing twelve-month return on equity of 11.40%.

ETFs with the largest weight of Catalent (NYSE:CTLT) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE), Alger 35 ETF (ATFV), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), SPDR S&P Pharmaceuticals ETF (XPH), VanEck Pharmaceutical ETF (PPH), Invesco Dynamic Biotechnology & Genome ETF (PBE), First Trust Nasdaq Pharmaceuticals ETF (FTXH) and Harbor Health Care ETF (MEDI).

Catalent issued an update on its FY 2023 earnings guidance on Tuesday, February, 7th. The company provided earnings per share (EPS) guidance of $3.13-$3.54 for the period, compared to the consensus earnings per share estimate of $3.20. The company issued revenue guidance of $4.63 billion-$4.88 billion, compared to the consensus revenue estimate of $4.69 billion.

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent's stock is owned by a number of retail and institutional investors. Top institutional investors include T. Rowe Price Investment Management Inc. (9.21%), Veritas Asset Management LLP (6.21%), Artisan Partners Limited Partnership (4.35%), American Century Companies Inc. (2.30%), Geode Capital Management LLC (2.01%) and Franklin Resources Inc. (1.84%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Gregory T Lucier, Gregory T Lucier, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano, Thomas W Hawkeswood and Wetteny Joseph.
View institutional ownership trends.

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CTLT stock can currently be purchased for approximately $64.27.

Catalent (NYSE:CTLT) has a market capitalization of $11.57 billion and generates $4.83 billion in revenue each year. The company earns $503 million in net income (profit) each year or $2.26 on an earnings per share basis.

The company employs 19,000 workers across the globe.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for the company is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at investors@catalent.com, or via fax at 732-537-6480.